Tissue Acquisition, Processing, and Pathology (TAPP) Core

$132,380P01FY2016CANIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 34663807 Paper 33341086 Paper 32069268 Paper 31420241 Paper 29550074 Paper 29508763 Paper 29399394 Paper 28862644 Paper 27258611 Paper 27045023 Paper 26979791 Paper 26973126 Paper 26968202 Paper 26330166 Paper 26324743 Paper 25979873 Paper 25941351 Paper 25600436 Paper 25104548 Paper 24919573 Paper 24778279 Paper 24719232 Paper 24579088 Paper 24439255 Paper 24329786 Paper 24274181 Paper 24018559 Paper 23883116 Paper 23865808 Paper 23576561 Paper 23486267 Paper 23481185 Paper 23481183 Paper 23411061 Paper 22742411 Paper 22348096 Paper 22054892 Paper 22008913 Paper 21838572 Paper 21819972 Paper 21642245 Paper 21610146 Paper 21148741 Paper 20980695 Paper 20926399 Paper 20700700 Paper 20683443 Paper 20118240 Paper 20068553 Paper 20028856 Paper 20016540 Paper 19859065 Paper 19773437 Paper 19732719 Paper 19715403 Paper 19211796 Paper 19074893 Paper 18841331 Paper 18559619 Paper 18463540 Paper 17671130 Paper 17638914 Paper 17617589 Paper 17582217 Paper 17332368 Paper 17080181 Paper 16488193 Paper 16397045 Paper 16357188 Paper 16325129 Paper 16243818 Paper 16166452 Paper 16166316 Paper 15846066 Paper 15622005 Paper 14633712 Paper 11916486 Paper 11578910 Paper 11228529 Paper 11202452 Paper 11020355 Paper 10955822 Paper 10770637 Paper 10694702

Abstract

PROJECT SUMMARY (See instructions): The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

View original record on NIH RePORTER →